Repeat cardiovascular-related procedures and real-world treatment in high-risk patients with hypercholesterolemia or mixed dyslipidemia.

Aim: To determine the real-world treatment patterns and recurrence of cardiovascular-related procedures and hospitalizations in patients at very-high atherosclerotic risk.

Methods: In this retrospective observational study, atherosclerotic cardiovascular disease (ASCVD)-related procedures and hospitalizations, and lipid-lowering therapy (LLT) medication data were assessed in adults with hypercholesterolemia or mixed dyslipidemia with an incident ASCVD-related procedure using health claims data from the German AOK PLUS (2010-2020) and GWQ ServicePlus databases (2013-2019). Differences in time-to-first event between LLT and non-LLT groups were assessed using a propensity score matched (PSM) comparison.

Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis.

This study assessed real-world treatment in patients with metastatic urothelial carcinoma (mUC) in Germany. Patients diagnosed with mUC from 2015 to 2019 were identified in two claims databases: AOK PLUS and GWQ. 3226 patients with mUC were analyzed; 1286 (39.

Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data.

Aims: This retrospective claims data study characterized real-world treatment patterns, healthcare resource utilization (HCRU), and costs in patients with metastatic urothelial carcinoma (mUC) in Germany.

Materials And Methods: Continuously insured adults with incident mUC diagnosis (=index; : C65-C68/C77-C79) in 2015-2019 were identified from two German claims databases. Patients who received first-line (1 L) treatment within 12 months of index were divided into three mutually exclusive sub-cohorts: platinum-based chemotherapy (PB-CT), non-PB-CT, and immunotherapy (IO).

A decade of chronic lymphocytic leukaemia therapy in Germany: Real-world treatment patterns and outcomes (2010-2022).

Pharmacotherapy options for chronic lymphocytic leukaemia (CLL) have expanded significantly in recent years. These options include chemotherapy, chemoimmunotherapy and signalling pathway inhibitors. A notable shift in the treatment landscape began with the widespread adoption of ibrutinib in 2016.

Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries.

Introduction: CAR T-cell therapy has emerged as a promising new immuno-oncology treatment that engages the patient's immune system to fight certain hematological malignancies, including diffuse large B-cell lymphoma (DLBCL). In the European Union (EU), CAR T-cell therapies have been approved for relapsed/refractory (R/R) DLBCL patients since 2018, but patient access is often still limited or delayed. This paper is aimed at discussing challenges to access and possible solutions in the largest four EU countries.